Pomerantz Law Firm Announces Class Action Lawsuit Against uniQure N.V. for Securities Fraud Allegations

Investor Alert: Class Action Lawsuit Against uniQure N.V.

Pomerantz Law Firm, a well-respected name in securities litigation, has initiated a class action lawsuit against uniQure N.V. (NASDAQ: QURE). This legal action concerns allegations of securities fraud and unlawful business practices by the company and some of its officials. Investors who have experienced financial losses related to uniQure's stock are encouraged to join the lawsuit, as they may be eligible for compensation.

Background of the Case

The class action highlights potential misleading statements made by uniQure regarding its investigational gene therapy, AMT-130, for treating Huntington's disease (HD). It was revealed in a press release dated November 3, 2025, that feedback from the U.S. Food and Drug Administration (FDA) was deemed unfavorable. The company indicated that the FDA might not consider the data from prior studies sufficient for a Biologics License Application (BLA).

In the press release, uniQure acknowledged a significant change in the FDA's stance from previous communications, particularly during multiple Type B meetings held in the preceding year. Such a shift raises concerns about the future of the drug's approval process and, consequently, the company's financial stability. Following the announcement, the stock price of uniQure plunged dramatically by 49.34%, raising alarm among investors.

Important Deadlines

Investors who purchased uniQure securities within the specified Class Period must take action promptly. April 13, 2026, is the deadline for interested parties to apply to be appointed as Lead Plaintiff in this class action. Those looking to take action are advised to reach out to Danielle Peyton at Pomerantz LLP via email or telephone. Providing personal details, including their address and the number of shares acquired, is recommended for efficient correspondence.

Significance of Pomerantz LLP

Founded by the notable Abraham L. Pomerantz, the firm has developed a reputation for holding corporations accountable. With a legacy spanning over 85 years, Pomerantz continues to advocate for the rights of investors harmed due to corporate misconduct. The firm has achieved numerous multimillion-dollar settlements, demonstrating its commitment to justice for victims of securities fraud.

For investors looking to understand their rights and options, Pomerantz LLP offers resources and further information on how to participate in this class action. Those interested can find more details and relevant documents on their website.

Conclusion

The ongoing situation at uniQure N.V. underlines the critical nature of transparency and accountability in the healthcare and biotechnology sectors. Investors are urged to remain vigilant, informed, and to seek legal counsel if they suspect that they may have been misled. The actions of Pomerantz LLP serve as a reminder of the essential role that legal oversight plays in protecting investor interests. Participation in this class action could potentially yield significant financial recovery for those affected by uniQure's alleged wrongdoing.

Stay updated with developments by following legal news and consulting with financial advisors to navigate these tumultuous times effectively.